SHIN NIPPON BIOMEDICAL LABORATORIES

Translational Research (TR), a division of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), has developed proprietary technology for nasal drug delivery, μco™ System ( "myu-co" system). The system is comprised of two technological elements, powder carrier technology and delivery device technology. In addition to licensing out platform technology and products developed in-house to pharmaceutical companies, SNBL provides support for R&D of drug products applying the group' s vast experience and capacity for drug development as a contract research organization (CRO) and its state-of-the-art preclinical and clinical study facilities recognized world-wide... We are researching and developing a proprietary nasal delivery system (NDS). SNBL's NDS, the μco™ System, consists of two technologies: a safe and muco-adhesive nasal drug carrier technology (in powder form), and a non-invasive and easy-to-use nasal delivery device.

Also known as: Shin Nippon Biomedical Laboratories, Ltd., SNBL Asset Management Co., Ltd., SNBL Nature Co., Ltd., SNBL U.S.A., Ltd.

Primary location: Tokyo Japan